SK, Arvelle sign $530m deal for antiepileptic drug cenobamate

This article was originally published here

Cenobamate is a novel and small molecule investigational antiepileptic drug being developed to treat partial-onset seizures in adult patients. Under exclusive licensing agreement, Arvelle will develop and commercialize

The post SK, Arvelle sign $530m deal for antiepileptic drug cenobamate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply